{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T12:26:06Z","timestamp":1788006366807,"version":"build-2784847793"},"reference-count":98,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Natural Science Foundation for Youth of Hunan Province","award":["No. 2022JJ40003"],"award-info":[{"award-number":["No. 2022JJ40003"]}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"crossref","award":["No.2024JJ7018"],"award-info":[{"award-number":["No.2024JJ7018"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Changde Science and Technology Board","award":["No.2023YD30"],"award-info":[{"award-number":["No.2023YD30"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1007\/s11033-025-11317-1","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T11:00:22Z","timestamp":1764759622000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunotherapy in multiple myeloma: advances from immune microenvironment insights to clinical application"],"prefix":"10.1007","volume":"53","author":[{"given":"Yao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuting","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiyun","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlian","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,3]]},"reference":[{"issue":"9","key":"11317_CR1","doi-asserted-by":"publisher","first-page":"e1406","DOI":"10.1634\/theoncologist.2020-0141","volume":"25","author":"H Ludwig","year":"2020","unstructured":"Ludwig H, Novis Durie S, Meckl A et al (2020) Multiple myeloma incidence and mortality around the Globe; interrelations between health access and Quality, economic Resources, and patient empowerment. Oncologist 25(9):e1406\u2013e13","journal-title":"Oncologist"},{"issue":"1","key":"11317_CR2","doi-asserted-by":"publisher","first-page":"2204","DOI":"10.1038\/s41598-024-83630-x","volume":"15","author":"Q Hou","year":"2025","unstructured":"Hou Q, Li X, Ma H et al (2025) A systematic epidemiological trends analysis study in global burden of multiple myeloma and 29 years forecast. Sci Rep 15(1):2204","journal-title":"Sci Rep"},{"key":"11317_CR3","doi-asserted-by":"publisher","first-page":"217272","DOI":"10.1016\/j.canlet.2024.217272","volume":"604","author":"S Huang","year":"2024","unstructured":"Huang S, Chung JY, Li C et al (2024) Cellular dynamics of tumor microenvironment driving immunotherapy resistance in non-small-cell lung carcinoma. Cancer Lett 604:217272","journal-title":"Cancer Lett"},{"issue":"2","key":"11317_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","volume":"14","author":"S Manier","year":"2017","unstructured":"Manier S, Salem KZ, Park J et al (2017) Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol 14(2):100\u2013113","journal-title":"Nat Rev Clin Oncol"},{"key":"11317_CR5","doi-asserted-by":"publisher","first-page":"216726","DOI":"10.1016\/j.canlet.2024.216726","volume":"588","author":"M Gao","year":"2024","unstructured":"Gao M, Shi J, Xiao X et al (2024) PD-1 regulation in immune homeostasis and immunotherapy. Cancer Lett 588:216726","journal-title":"Cancer Lett"},{"issue":"1","key":"11317_CR6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41392-024-02118-2","volume":"10","author":"GQ Zhu","year":"2025","unstructured":"Zhu GQ, Tang Z, Chu TH et al (2025) Targeting SRSF1 improves cancer immunotherapy by dually acting on CD8(+)T and tumor cells. Signal Transduct Target Ther 10(1):25","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"11317_CR7","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41423-023-00990-6","volume":"20","author":"A Del Prete","year":"2023","unstructured":"Del Prete A, Salvi V, Soriani A et al (2023) Dendritic cell subsets in cancer immunity and tumor antigen sensing. Cell Mol Immunol 20(5):432\u2013447","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"11317_CR8","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/s41392-024-02005-w","volume":"9","author":"S Chen","year":"2024","unstructured":"Chen S, Zhu H, Jounaidi Y (2024) Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization. Signal Transduct Target Ther 9(1):302","journal-title":"Signal Transduct Target Ther"},{"issue":"8","key":"11317_CR9","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41577-020-00490-y","volume":"21","author":"F Veglia","year":"2021","unstructured":"Veglia F, Sanseviero E, Gabrilovich DI (2021) Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity. Nat Rev Immunol 21(8):485\u2013498","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"11317_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/s41571-024-00870-6","volume":"21","author":"S Kumagai","year":"2024","unstructured":"Kumagai S, Itahashi K, Nishikawa H (2024) Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine. Nat Rev Clin Oncol 21(5):337\u2013353","journal-title":"Nat Rev Clin Oncol"},{"key":"11317_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147575","author":"JY Chung","year":"2021","unstructured":"Chung JY, Chan MK, Li JS et al (2021) TGF-\u03b2 signaling: from tissue fibrosis to tumor microenvironment. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms22147575","journal-title":"Int J Mol Sci"},{"key":"11317_CR12","doi-asserted-by":"publisher","DOI":"10.1177\/20503121211069012","volume":"10","author":"B Mirlekar","year":"2022","unstructured":"Mirlekar B (2022) Tumor promoting roles of IL-10, TGF-\u03b2, IL-4, and IL-35: its implications in cancer immunotherapy. SAGE Open Med 10:20503121211069012","journal-title":"SAGE Open Med"},{"issue":"11","key":"11317_CR13","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.it.2022.09.007","volume":"43","author":"S Pinto","year":"2022","unstructured":"Pinto S, Pahl J, Schottelius A et al (2022) Reimagining antibody-dependent cellular cytotoxicity in cancer: the potential of natural killer cell engagers. Trends Immunol 43(11):932\u201346","journal-title":"Trends Immunol"},{"key":"11317_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2025.217498","author":"TA Lee","year":"2025","unstructured":"Lee TA, Tsai EY, Liu SH et al (2025) Regulation of PD-L1 glycosylation and advances in cancer immunotherapy. Cancer Lett. https:\/\/doi.org\/10.1016\/j.canlet.2025.217498","journal-title":"Cancer Lett"},{"issue":"1","key":"11317_CR15","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2005-08-3101","volume":"107","author":"RH Prabhala","year":"2006","unstructured":"Prabhala RH, Neri P, Bae JE et al (2006) Dysfunctional T regulatory cells in multiple myeloma. Blood 107(1):301\u2013304","journal-title":"Blood"},{"issue":"15","key":"11317_CR16","doi-asserted-by":"publisher","first-page":"2975","DOI":"10.1182\/blood-2012-08-448548","volume":"121","author":"GT G\u00f6rg\u00fcn","year":"2013","unstructured":"G\u00f6rg\u00fcn GT, Whitehill G, Anderson JL et al (2013) Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood 121(15):2975\u20132987","journal-title":"Blood"},{"issue":"6","key":"11317_CR17","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen AD, Garfall AL, Stadtmauer EA et al (2019) B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J Clin Invest 129(6):2210\u201321","journal-title":"J Clin Invest"},{"issue":"4","key":"11317_CR18","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","volume":"27","author":"MC Da Vi\u00e0","year":"2021","unstructured":"Da Vi\u00e0 MC, Dietrich O, Truger M et al (2021) Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma. Nat Med 27(4):616\u2013619","journal-title":"Nat Med"},{"key":"11317_CR19","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","volume":"6","author":"SA Laurent","year":"2015","unstructured":"Laurent SA, Hoffmann FS, Kuhn PH et al (2015) \u03b3-Secretase directly sheds the survival receptor BCMA from plasma cells. Nat Commun 6:7333","journal-title":"Nat Commun"},{"issue":"6","key":"11317_CR20","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/j.1365-2141.2012.09241.x","volume":"158","author":"E Sanchez","year":"2012","unstructured":"Sanchez E, Li M, Kitto A et al (2012) Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol 158(6):727\u201338","journal-title":"Br J Haematol"},{"issue":"1","key":"11317_CR21","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","volume":"12","author":"MK Samur","year":"2021","unstructured":"Samur MK, Fulciniti M, Aktas Samur A et al (2021) Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun 12(1):868","journal-title":"Nat Commun"},{"issue":"9","key":"11317_CR22","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1158\/2326-6066.CIR-24-1313","volume":"13","author":"LG Rodr\u00edguez-Lobato","year":"2025","unstructured":"Rodr\u00edguez-Lobato LG, Card\u00fas O, Ma\u00f1\u00e9-Pujol J et al (2025) Bicistronic CAR T cell against BCMA and CD229 effectively controls myeloma even when BCMA expression is limited. Cancer Immunol Res 13(9):1374\u201390","journal-title":"Cancer Immunol Res"},{"issue":"8","key":"11317_CR23","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nri3862","volume":"15","author":"EJ Wherry","year":"2015","unstructured":"Wherry EJ, Kurachi M (2015) Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15(8):486\u2013499","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"11317_CR24","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta JA, Lacey SF, Orlando EJ et al (2018) Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med 24(5):563\u2013571","journal-title":"Nat Med"},{"issue":"95","key":"11317_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adj7970","volume":"9","author":"M Kilian","year":"2024","unstructured":"Kilian M, Friedrich MJ, Lu KH et al (2024) The immunoglobulin superfamily ligand B7H6 subjects T cell responses to NK cell surveillance. Sci Immunol 9(95):eadj7970","journal-title":"Sci Immunol"},{"issue":"1","key":"11317_CR26","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/s12943-024-02079-8","volume":"23","author":"X Xia","year":"2024","unstructured":"Xia X, Yang Z, Lu Q et al (2024) Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy. Mol Cancer 23(1):175","journal-title":"Mol Cancer"},{"issue":"Supplement 1","key":"11317_CR27","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1182\/blood-2024-200181","volume":"144","author":"A D'Souza","year":"2024","unstructured":"D\u2019Souza A, Costa LJ, San-Miguel JF et al (2024) Teclistamab, daratumumab, and pomalidomide in patients with relapsed\/refractory multiple myeloma: results from the Majestec-2 cohort a and Trimm-2 studies. Blood 144(Supplement 1):495","journal-title":"Blood"},{"issue":"10","key":"11317_CR28","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1358\/dot.2021.57.10.3313853","volume":"57","author":"SR Goldsmith","year":"2021","unstructured":"Goldsmith SR, Foley N, Schroeder MA (2021) Daratumumab for the treatment of multiple myeloma. Drugs Today (Barc) 57(10):591\u2013605","journal-title":"Drugs Today (Barc)"},{"issue":"11","key":"11317_CR29","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, Kumar SK, Plesner T et al (2021) Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol 22(11):1582\u201396","journal-title":"Lancet Oncol"},{"issue":"8","key":"11317_CR30","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1200\/JCO.21.02734","volume":"41","author":"P Sonneveld","year":"2023","unstructured":"Sonneveld P, Chanan-Khan A, Weisel K et al (2023) Overall survival with daratumumab, bortezomib, and dexamethasone in previously treated multiple myeloma (CASTOR): a randomized, open-label, phase III trial. J Clin Oncol 41(8):1600\u20139","journal-title":"J Clin Oncol"},{"issue":"4","key":"11317_CR31","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, Dimopoulos MA, Boccadoro M et al (2024) Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med 390(4):301\u2013313","journal-title":"N Engl J Med"},{"key":"11317_CR32","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.3389\/fimmu.2020.01771","volume":"11","author":"C Zhu","year":"2020","unstructured":"Zhu C, Song Z, Wang A et al (2020) Isatuximab acts through Fc-dependent, independent, and direct pathways to kill multiple myeloma cells. Front Immunol 11:1771","journal-title":"Front Immunol"},{"issue":"11","key":"11317_CR33","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1200\/JCO-24-02266","volume":"43","author":"EK Mai","year":"2025","unstructured":"Mai EK, Bertsch U, Pozek E et al (2025) Isatuximab, lenalidomide, bortezomib, and dexamethasone induction therapy for transplant-eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial. J Clin Oncol 43(11):1279\u201388","journal-title":"J Clin Oncol"},{"key":"11317_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1240061","volume":"13","author":"S Li","year":"2023","unstructured":"Li S, Chen D, Guo H et al (2023) The novel high-affinity humanized antibody IMM40H targets CD70, eliminates tumors via Fc-mediated effector functions, and interrupts CD70\/CD27 signaling. Front Oncol 13:1240061","journal-title":"Front Oncol"},{"issue":"3","key":"11317_CR35","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40265-016-0540-0","volume":"76","author":"A Markham","year":"2016","unstructured":"Markham A (2016) Elotuzumab: first global approval. Drugs 76(3):397\u2013403","journal-title":"Drugs"},{"issue":"19","key":"11317_CR36","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S et al (2018) Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med 379(19):1811\u20131822","journal-title":"N Engl J Med"},{"issue":"7","key":"11317_CR37","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A et al (2015) Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med 373(7):621\u2013631","journal-title":"N Engl J Med"},{"issue":"21","key":"11317_CR38","doi-asserted-by":"publisher","first-page":"4629","DOI":"10.1158\/1078-0432.CCR-22-0618","volume":"28","author":"AC Baines","year":"2022","unstructured":"Baines AC, Ershler R, Kanapuru B et al (2022) FDA approval summary: belantamab mafodotin for patients with relapsed or refractory multiple myeloma. Clin Cancer Res 28(21):4629\u201333","journal-title":"Clin Cancer Res"},{"issue":"2","key":"11317_CR39","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"S Lonial","year":"2020","unstructured":"Lonial S, Lee HC, Badros A et al (2020) Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. Lancet Oncol 21(2):207\u201321","journal-title":"Lancet Oncol"},{"issue":"5","key":"11317_CR40","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2405090","volume":"391","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M et al (2024) Belantamab mafodotin, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med 391(5):393\u2013407","journal-title":"N Engl J Med"},{"issue":"5","key":"11317_CR41","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/s41417-024-00750-2","volume":"31","author":"M Sheykhhasan","year":"2024","unstructured":"Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R et al (2024) CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Ther 31(5):667\u2013686","journal-title":"Cancer Gene Ther"},{"key":"11317_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13112639","author":"M Martino","year":"2021","unstructured":"Martino M, Canale FA, Alati C et al (2021) CART-cell therapy: recent advances and new evidence in multiple myeloma. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13112639","journal-title":"Cancers (Basel)"},{"issue":"8","key":"11317_CR43","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi NC, Anderson LD Jr., Shah N et al (2021) Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med 384(8):705\u2013716","journal-title":"N Engl J Med"},{"issue":"11","key":"11317_CR44","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"P Rodriguez-Otero","year":"2023","unstructured":"Rodriguez-Otero P, Ailawadhi S, Arnulf B et al (2023) Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med 388(11):1002\u20131014","journal-title":"N Engl J Med"},{"issue":"10297","key":"11317_CR45","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","volume":"398","author":"JG Berdeja","year":"2021","unstructured":"Berdeja JG, Madduri D, Usmani SZ et al (2021) Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b\/2 open-label study. Lancet 398(10297):314\u201324","journal-title":"Lancet"},{"issue":"1","key":"11317_CR46","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1080\/03007995.2022.2139052","volume":"39","author":"T Martin","year":"2023","unstructured":"Martin T, Usmani SZ, Schecter JM et al (2023) Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma. Curr Med Res Opin 39(1):81\u20139","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"11317_CR47","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1080\/07853890.2021.1970218","volume":"53","author":"L Zhang","year":"2021","unstructured":"Zhang L, Shen X, Yu W et al (2021) Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma. Ann Med 53(1):1547\u201359","journal-title":"Ann Med"},{"issue":"1","key":"11317_CR48","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s40364-024-00634-5","volume":"12","author":"F Nasiri","year":"2024","unstructured":"Nasiri F, Asaadi Y, Mirzadeh F et al (2024) Updates on CAR T cell therapy in multiple myeloma. Biomark Res 12(1):102","journal-title":"Biomark Res"},{"issue":"2","key":"11317_CR49","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1182\/bloodadvances.2023011992","volume":"8","author":"C Baguet","year":"2024","unstructured":"Baguet C, Larghero J, Mebarki M (2024) Early predictive factors of failure in autologous CAR T-cell manufacturing and\/or efficacy in hematologic malignancies. Blood Adv 8(2):337\u2013342","journal-title":"Blood Adv"},{"key":"11317_CR50","doi-asserted-by":"publisher","first-page":"1275329","DOI":"10.3389\/fimmu.2023.1275329","volume":"14","author":"AF Binder","year":"2023","unstructured":"Binder AF, Walker CJ, Mark TM et al (2023) Impacting T-cell fitness in multiple myeloma: potential roles for Selinexor and XPO1 inhibitors. Front Immunol 14:1275329","journal-title":"Front Immunol"},{"issue":"1","key":"11317_CR51","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12967-024-05063-4","volume":"22","author":"T Poiret","year":"2024","unstructured":"Poiret T, Vikberg S, Schoutrop E et al (2024) CAR T cells and T cells phenotype and function are impacted by glucocorticoid exposure with different magnitude. J Transl Med 22(1):273","journal-title":"J Transl Med"},{"issue":"11","key":"11317_CR52","doi-asserted-by":"publisher","first-page":"5327","DOI":"10.1016\/j.ymthe.2025.07.045","volume":"33","author":"B Vega-Blanco","year":"2025","unstructured":"Vega-Blanco B, Mfarrej B, Lu HJ et al (2025) Advancing CAR-T cell therapy: insights into patient biology, leukapheresis, and cryopreservation. Mol Ther 33(11):5327\u20135337","journal-title":"Mol Ther"},{"issue":"1","key":"11317_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-025-01714-1","volume":"18","author":"H Yao","year":"2025","unstructured":"Yao H, Ren SH, Wang LH et al (2025) Correction: BCMA\/GPRC5D bispecific CAR T-cell therapy for relapsed\/refractory multiple myeloma with extramedullary disease: a single-center, single-arm, phase 1 trial. J Hematol Oncol 18(1):60","journal-title":"J Hematol Oncol"},{"issue":"2","key":"11317_CR54","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","volume":"1","author":"C Fern\u00e1ndez de Larrea","year":"2020","unstructured":"Fern\u00e1ndez de Larrea C, Staehr M, Lopez AV et al (2020) Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma. Blood Cancer Discov 1(2):146\u2013154","journal-title":"Blood Cancer Discov"},{"issue":"10","key":"11317_CR55","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1016\/S2352-3026(24)00176-5","volume":"11","author":"D Zhou","year":"2024","unstructured":"Zhou D, Sun Q, Xia J et al (2024) Anti-BCMA\/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trial. Lancet Haematol 11(10):e751\u2013e60","journal-title":"Lancet Haematol"},{"issue":"1","key":"11317_CR56","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13046-021-02214-z","volume":"41","author":"Y Tang","year":"2022","unstructured":"Tang Y, Yin H, Zhao X et al (2022) High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma. J Exp Clin Cancer Res 41(1):2","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"11317_CR57","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1158\/1078-0432.CCR-23-3759","volume":"30","author":"A Oliver-Caldes","year":"2024","unstructured":"Oliver-Caldes A, Espa\u00f1ol-Rego M, Zabaleta A et al (2024) Biomarkers of efficacy and safety of the academic BCMA-CART ARI0002h for the treatment of refractory multiple myeloma. Clin Cancer Res 30(10):2085\u201396","journal-title":"Clin Cancer Res"},{"issue":"1","key":"11317_CR58","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1038\/s41467-024-44873-4","volume":"15","author":"F Sun","year":"2024","unstructured":"Sun F, Cheng Y, Wanchai V et al (2024) Bispecific BCMA\/CD24 CAR-T cells control multiple myeloma growth. Nat Commun 15(1):615","journal-title":"Nat Commun"},{"issue":"2","key":"11317_CR59","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1158\/2643-3230.BCD-22-0074","volume":"4","author":"AL Garfall","year":"2023","unstructured":"Garfall AL, Cohen AD, Susanibar-Adaniya SP et al (2023) Anti-BCMA\/CD19 CAR T cells with early immunomodulatory maintenance for multiple myeloma responding to initial or later-line therapy. Blood Cancer Discov 4(2):118\u2013133","journal-title":"Blood Cancer Discov"},{"key":"11317_CR60","doi-asserted-by":"publisher","DOI":"10.1172\/JCI171396","author":"F Sun","year":"2024","unstructured":"Sun F, Cheng Y, Chen JR et al (2024) BCMA- and CST6-specific CAR T cells lyse multiple myeloma cells and suppress murine osteolytic lesions. J Clin Invest. https:\/\/doi.org\/10.1172\/JCI171396","journal-title":"J Clin Invest"},{"issue":"1","key":"11317_CR61","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12951-024-02512-6","volume":"22","author":"Q Lu","year":"2024","unstructured":"Lu Q, Li H, Wu Z et al (2024) BCMA\/CD47-directed universal CAR-T cells exhibit excellent antitumor activity in multiple myeloma. J Nanobiotechnol 22(1):279","journal-title":"J Nanobiotechnol"},{"issue":"12","key":"11317_CR62","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1038\/s41591-023-02306-7","volume":"29","author":"S Mailankody","year":"2023","unstructured":"Mailankody S, Matous JV, Chhabra S et al (2023) Publisher correction: allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results. Nat Med 29(12):3271","journal-title":"Nat Med"},{"issue":"4","key":"11317_CR63","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1158\/2326-6066.CIR-23-0679","volume":"12","author":"\u00c9 Degagn\u00e9","year":"2024","unstructured":"Degagn\u00e9 \u00c9, Donohoue PD, Roy S et al (2024) High-Specificity CRISPR-Mediated genome engineering in Anti-BCMA allogeneic CAR T cells suppresses allograft rejection in preclinical models. Cancer Immunol Res 12(4):462\u2013477","journal-title":"Cancer Immunol Res"},{"key":"11317_CR64","doi-asserted-by":"publisher","first-page":"762","DOI":"10.3389\/fimmu.2020.00762","volume":"11","author":"M Lejeune","year":"2020","unstructured":"Lejeune M, K\u00f6se MC, Duray E et al (2020) Bispecific, T-cell-recruiting antibodies in B-cell malignancies. Front Immunol 11:762","journal-title":"Front Immunol"},{"key":"11317_CR65","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.760382","volume":"11","author":"FM Uckun","year":"2021","unstructured":"Uckun FM (2021) Dual targeting of multiple myeloma stem cells and myeloid-derived suppressor cells for treatment of chemotherapy-resistant multiple myeloma. Front Oncol 11:760382","journal-title":"Front Oncol"},{"issue":"9","key":"11317_CR66","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/j.clml.2019.08.002","volume":"19","author":"D Madduri","year":"2019","unstructured":"Madduri D, Dhodapkar MV, Lonial S et al (2019) SOHO state of the art updates and next questions: T-cell-directed immune therapies for multiple myeloma: chimeric antigen receptor-modified T cells and bispecific T-cell-engaging agents. Clin Lymphoma Myeloma Leuk 19(9):537\u201344","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"8","key":"11317_CR67","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1200\/JCO.19.02657","volume":"38","author":"MS Topp","year":"2020","unstructured":"Topp MS, Duell J, Zugmaier G et al (2020) Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol 38(8):775\u201383","journal-title":"J Clin Oncol"},{"issue":"16","key":"11317_CR68","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s40265-022-01793-1","volume":"82","author":"C Kang","year":"2022","unstructured":"Kang C (2022) Teclistamab: first approval. Drugs 82(16):1613\u20139","journal-title":"Drugs"},{"issue":"6","key":"11317_CR69","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"P Moreau","year":"2022","unstructured":"Moreau P, Garfall AL, van de Donk N et al (2022) Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 387(6):495\u2013505","journal-title":"N Engl J Med"},{"issue":"10301","key":"11317_CR70","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","volume":"398","author":"SZ Usmani","year":"2021","unstructured":"Usmani SZ, Garfall AL, van de Donk N et al (2021) Teclistamab, a B-cell maturation antigen\u2008\u00d7\u2008CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study. Lancet 398(10301):665\u2013674","journal-title":"Lancet"},{"issue":"3","key":"11317_CR71","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.clml.2023.11.001","volume":"24","author":"TG Martin","year":"2024","unstructured":"Martin TG, Moreau P, Usmani SZ et al (2024) Teclistamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: results from the phase II MajesTEC-1 study. Clin Lymphoma Myeloma Leuk 24(3):194\u2013202","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"10","key":"11317_CR72","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.clml.2024.05.003","volume":"24","author":"A Chari","year":"2024","unstructured":"Chari A, Krishnan A, Rasche L et al (2024) Clinical management of patients with Relapsed\/Refractory multiple myeloma treated with Talquetamab. Clin Lymphoma Myeloma Leuk 24(10):665\u201393e14","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"6","key":"11317_CR73","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/CCO.0000000000000983","volume":"35","author":"N van de Donk","year":"2023","unstructured":"van de Donk N, O\u2019Neill C, de Ruijter MEM et al (2023) T-cell redirecting bispecific and trispecific antibodies in multiple myeloma beyond BCMA. Curr Opin Oncol 35(6):601\u201311","journal-title":"Curr Opin Oncol"},{"issue":"9","key":"11317_CR74","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"AM Lesokhin","year":"2023","unstructured":"Lesokhin AM, Tomasson MH, Arnulf B et al (2023) Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results. Nat Med 29(9):2259\u20132267","journal-title":"Nat Med"},{"issue":"2","key":"11317_CR75","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2406536","volume":"392","author":"YC Cohen","year":"2025","unstructured":"Cohen YC, Magen H, Gatt M et al (2025) Talquetamab plus Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med 392(2):138\u2013149","journal-title":"N Engl J Med"},{"issue":"1","key":"11317_CR76","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s13045-022-01296-2","volume":"15","author":"D Kegyes","year":"2022","unstructured":"Kegyes D, Constantinescu C, Vrancken L et al (2022) Patient selection for CAR T or bite therapy in multiple myeloma: which treatment for each patient? J Hematol Oncol 15(1):78","journal-title":"J Hematol Oncol"},{"issue":"1","key":"11317_CR77","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1111\/imcb.1003","volume":"96","author":"V Sasidharan Nair","year":"2018","unstructured":"Sasidharan Nair V, Elkord E (2018) Immune checkpoint inhibitors in cancer therapy: a focus on T-regulatory cells. Immunol Cell Biol 96(1):21\u201333","journal-title":"Immunol Cell Biol"},{"issue":"6","key":"11317_CR78","first-page":"1803","volume":"30","author":"QZ Li","year":"2022","unstructured":"Li QZ, Peng J, Chen HM et al (2022) [Expression and significance of PD-1, PD-L1 and CTLA-4 in the bone marrow of patients with multiple Myeloma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi 30(6):1803\u20131809","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"issue":"23","key":"11317_CR79","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","volume":"34","author":"AM Lesokhin","year":"2016","unstructured":"Lesokhin AM, Ansell SM, Armand P et al (2016) Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol 34(23):2698\u2013704","journal-title":"J Clin Oncol"},{"issue":"15","key":"11317_CR80","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1002\/cncr.35319","volume":"130","author":"A Suvannasankha","year":"2024","unstructured":"Suvannasankha A, Bahlis N, Trudel S et al (2024) Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma. Cancer 130(15):2629\u20132641","journal-title":"Cancer"},{"issue":"9","key":"11317_CR81","doi-asserted-by":"publisher","first-page":"10254","DOI":"10.1002\/cam4.5753","volume":"12","author":"A Lesokhin","year":"2023","unstructured":"Lesokhin A, LeBlanc R, Dimopoulos MA et al (2023) Isatuximab in combination with cemiplimab in patients with relapsed\/refractory multiple myeloma: a phase 1\/2 study. Cancer Med 12(9):10254\u201366","journal-title":"Cancer Med"},{"key":"11317_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020164","author":"F Costa","year":"2021","unstructured":"Costa F, Marchica V, Storti P et al (2021) PD-L1\/PD-1 axis in multiple myeloma microenvironment and a possible link with CD38-mediated immune-suppression. Cancers (Basel). https:\/\/doi.org\/10.3390\/cancers13020164","journal-title":"Cancers (Basel)"},{"issue":"1","key":"11317_CR83","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1186\/s12885-021-08588-9","volume":"21","author":"W Ye","year":"2021","unstructured":"Ye W, Wu X, Liu X et al (2021) Comparison of monoclonal antibodies targeting CD38, SLAMF7 and PD-1\/PD-L1 in combination with bortezomib\/immunomodulators plus dexamethasone\/prednisone for the treatment of multiple myeloma: an indirect-comparison meta-analysis of randomised controlled trials. BMC Cancer 21(1):994","journal-title":"BMC Cancer"},{"issue":"11","key":"11317_CR84","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1182\/bloodadvances.2019000191","volume":"3","author":"AZ Badros","year":"2019","unstructured":"Badros AZ, Ma N, Rapoport AP et al (2019) Long-term remissions after stopping pembrolizumab for relapsed or refractory multiple myeloma. Blood Adv 3(11):1658\u201360","journal-title":"Blood Adv"},{"issue":"10","key":"11317_CR85","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1182\/blood-2017-03-775122","volume":"130","author":"A Badros","year":"2017","unstructured":"Badros A, Hyjek E, Ma N et al (2017) Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed\/refractory multiple myeloma. Blood 130(10):1189\u20131197","journal-title":"Blood"},{"issue":"9","key":"11317_CR86","doi-asserted-by":"publisher","first-page":"e459","DOI":"10.1016\/S2352-3026(19)30110-3","volume":"6","author":"MV Mateos","year":"2019","unstructured":"Mateos MV, Blacklock H, Schjesvold F et al (2019) Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial. Lancet Haematol 6(9):e459\u2013e69","journal-title":"Lancet Haematol"},{"issue":"9","key":"11317_CR87","doi-asserted-by":"publisher","first-page":"e448","DOI":"10.1016\/S2352-3026(19)30109-7","volume":"6","author":"SZ Usmani","year":"2019","unstructured":"Usmani SZ, Schjesvold F, Oriol A et al (2019) Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. Lancet Haematol 6(9):e448\u2013e58","journal-title":"Lancet Haematol"},{"issue":"1","key":"11317_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-023-01499-1","volume":"16","author":"L Cai","year":"2023","unstructured":"Cai L, Li Y, Tan J et al (2023) Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy. J Hematol Oncol 16(1):101","journal-title":"J Hematol Oncol"},{"issue":"2","key":"11317_CR89","doi-asserted-by":"publisher","first-page":"E32","DOI":"10.1002\/ajh.27161","volume":"99","author":"AM Brunner","year":"2024","unstructured":"Brunner AM, Esteve J, Porkka K et al (2024) Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromes. Am J Hematol 99(2):E32-e6","journal-title":"Am J Hematol"},{"key":"11317_CR90","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqae083","author":"PP Patwardhan","year":"2024","unstructured":"Patwardhan PP, Franz J, Agha M et al (2024) Persistent cytopenias after anti-BCMA CAR T-cell therapy are associated with reduced hematopoietic activity in posttreatment bone marrows. Am J Clin Pathol. https:\/\/doi.org\/10.1093\/ajcp\/aqae083","journal-title":"Am J Clin Pathol"},{"issue":"12","key":"11317_CR91","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1182\/bloodadvances.2025015981","volume":"9","author":"JN Gustine","year":"2025","unstructured":"Gustine JN, Branagan AR, Cirstea DD et al (2025) Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in multiple myeloma. Blood Adv 9(12):3026\u201330","journal-title":"Blood Adv"},{"key":"11317_CR92","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau7746","author":"EL Smith","year":"2019","unstructured":"Smith EL, Harrington K, Staehr M et al (2019) GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. Sci Transl Med. https:\/\/doi.org\/10.1126\/scitranslmed.aau7746","journal-title":"Sci Transl Med"},{"issue":"2","key":"11317_CR93","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1016\/S2352-3026(22)00372-6","volume":"10","author":"M Zhang","year":"2023","unstructured":"Zhang M, Wei G, Zhou L et al (2023) GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol 10(2):e107\u2013e16","journal-title":"Lancet Haematol"},{"issue":"1","key":"11317_CR94","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1038\/s41467-023-39395-4","volume":"14","author":"D Jiang","year":"2023","unstructured":"Jiang D, Huang H, Qin H et al (2023) Chimeric antigen receptor T cells targeting FcRH5 provide robust tumour-specific responses in murine xenograft models of multiple myeloma. Nat Commun 14(1):3642","journal-title":"Nat Commun"},{"issue":"1","key":"11317_CR95","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","volume":"7","author":"LJ Rupp","year":"2017","unstructured":"Rupp LJ, Schumann K, Roybal KT et al (2017) CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells. Sci Rep 7(1):737","journal-title":"Sci Rep"},{"issue":"8","key":"11317_CR96","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1016\/j.ccell.2024.07.002","volume":"42","author":"U Uslu","year":"2024","unstructured":"Uslu U, Castelli S, June CH (2024) CAR T cell combination therapies to treat cancer. Cancer Cell 42(8):1319\u20131325","journal-title":"Cancer Cell"},{"key":"11317_CR97","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.834002","volume":"12","author":"E Elmas","year":"2022","unstructured":"Elmas E, Saljoughian N, de Souza Fernans Pereira M et al (2022) CRISPR gene editing of human primary NK and T cells for cancer immunotherapy. Front Oncol 12:834002","journal-title":"Front Oncol"},{"issue":"9","key":"11317_CR98","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/j.stem.2024.06.009","volume":"31","author":"JL Thangaraj","year":"2024","unstructured":"Thangaraj JL, Coffey M, Lopez E et al (2024) Disruption of TGF-\u03b2 signaling pathway is required to mediate effective killing of hepatocellular carcinoma by human iPSC-derived NK cells. Cell Stem Cell 31(9):1327\u201343e5","journal-title":"Cell Stem Cell"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11317-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-11317-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-11317-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T12:02:19Z","timestamp":1764763339000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-11317-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,3]]},"references-count":98,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["11317"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-11317-1","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,3]]},"assertion":[{"value":"4 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All the named authors have read and approved the manuscript for publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"158"}}